Open R&D: we build the future of Zambon
The value of a business open to research
We wish to establish a pipeline of proprietary products with a global presence, relying on the knowledge, talent and skills of all those who work within the company as well as those who work with us from outside the company. At Zambon, this research goal is based on cooperation with a network of research centers across the world.
Our focus
We are moving from having many local projects toward establishing a global pipeline focused on specialties, with the aim of exploring new potential therapeutic indications and developing new proprietary drugs in new fields.
Looking to the future
We continue to look to the future by exploring new ways of conducting R&D, using Big Data and new technologies based on machine learning.
Our pipeline
Our ongoing clinical trials
PIPELINE - Respiratory
Preclinical
Phase 1
Phase 2
Phase 3
Phase 4
Phase 3
US: CMS & I-Neb for Non-Cystic Fibrosis Bronchiectasis (NCFB)
Phase 3
EU: CMS & I-Neb for Non-Cystic Fibrosis Bronchiectasis (NCFB)
Phase 2
Phase 3
US: CMS & I-Neb Cystic Fibrosis (CF)
PIPELINE - Anti-infectives
Preclinical
Phase 1
Phase 2
Phase 3
Phase 4
Preclinical
Novel antibiotic
Preclinical
Inhaled product for pulmonary fungal infection
PIPELINE - CNS: Parkinson's Disease
Preclinical
Phase 1
Phase 2
Phase 3
Phase 4
Phase 3
Safinamide for levodopa-induced dyskinesia
Phase 4
Safinamide for Pain in PD patients
Phase 2
Safinamide for MSA
FIND OUT MORE ABOUT OTHER AREAS
Our focus
Zambon's daily commitment: improving the lives of patients.